Showing studies related to your query18 results shown

Program Matched

Atacicept

Vera Therapeutics

Dual BAFF/APRIL inhibitor. ORIGIN-3 Phase 3 met primary endpoint (46% proteinuria reduction vs placebo, p<0.0001). BLA filed Nov 2025. FDA decision expected 202…

IgA Nephropathy

Studies (18 shown)

NCT07020923PHASE2ACTIVE_NOT_RECRUITING

Monthly Dosing of Atacicept in IgAN

Sponsor · Vera Therapeutics, Inc.Condition · IgA Nephropathy (IgAN), Berger DiseaseIntervention · AtaciceptUpdated Apr 2026
NCT06983028PHASE2RECRUITING

Atacicept in Multiple Glomerular Diseases

Sponsor · Vera Therapeutics, Inc.Condition · pMN, IgANIntervention · AtaciceptUpdated Jan 2026
NCT04716231PHASE3ACTIVE_NOT_RECRUITING

Atacicept in Subjects With IgA Nephropathy

Sponsor · Vera Therapeutics, Inc.Condition · IgA Nephropathy, Berger DiseaseIntervention · Atacicept, Placebo to match AtaciceptUpdated Sep 2025
NCT05609812PHASE3WITHDRAWN

Atacicept in Subjects With Active Lupus Nephritis (COMPASS)

Sponsor · Vera Therapeutics, Inc.Condition · Lupus Nephritis (LN)Intervention · Atacicept, PlaceboUpdated May 2025
NCT06674577PHASE2ENROLLING_BY_INVITATION

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Atacicept

Sponsor · Vera Therapeutics, Inc.Condition · IgA Nephropathy (IgAN), Renal and Urinary DisordersIntervention · Atacicept 150 mgUpdated Apr 2025
NCT02808429PHASE2TERMINATED

Efficacy and Safety of Atacicept in IgA Nephropathy

Sponsor · EMD Serono Research & Development Institute, Inc.Condition · IgA NephropathyIntervention · Placebo, Atacicept 25 mgUpdated Feb 2021
NCT02070978PHASE2TERMINATED

Long-term Safety and Tolerability of Atacicept (Long-term Follow-Up of Participant Who Participated in ADDRESS II)

Sponsor · EMD SeronoCondition · Lupus Erythematosus, SystemicIntervention · Atacicept 75 mg, Atacicept 150 mgUpdated Mar 2019
NCT01972568PHASE2COMPLETED

Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus

Sponsor · EMD SeronoCondition · Lupus Erythematosus, SystemicIntervention · Atacicept 75 milligram (mg), Atacicept 150 mgUpdated Jan 2018
NCT00853762PHASE2TERMINATED

Atacicept in Multiple Sclerosis Extension Study, Phase II

Sponsor · EMD SeronoCondition · Relapsing Multiple SclerosisIntervention · Atacicept 25 mg, Atacicept 75 mgUpdated Mar 2017
NCT00664521PHASE2COMPLETED

Atacicept in Combination With Rituximab in Subjects With Rheumatoid Arthritis (August III)

Sponsor · Merck KGaA, Darmstadt, GermanyCondition · Rheumatoid ArthritisIntervention · Rituximab, AtaciceptUpdated Dec 2016
NCT00642902PHASE2TERMINATED

A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS)

Sponsor · EMD SeronoCondition · Relapsing Multiple SclerosisIntervention · Atacicept, AtaciceptUpdated May 2016
NCT00573157PHASE2, PHASE3TERMINATED

The Efficacy and Safety of Atacicept in Combination With Mycophenolate Mofetil Used to Treat Lupus Nephritis

Sponsor · EMD SeronoCondition · Lupus NephritisIntervention · Atacicept, Mycophenolate mofetilUpdated Mar 2016
NCT00624338PHASE2, PHASE3COMPLETED

Atacicept Phase 2/3 in Generalized Systemic Lupus Erythematosus (APRIL-SLE)

Sponsor · EMD SeronoCondition · Lupus Erythematosus, SystemicIntervention · Atacicept 75 mg, Atacicept 150 mgUpdated Mar 2016
NCT00595413PHASE2COMPLETED

Atacicept in Anti-Tumor Necrosis Factor Alpha-naïve Subjects With Rheumatoid Arthritis (AUGUST II)

Sponsor · EMD SeronoCondition · Rheumatoid ArthritisIntervention · Placebo matched to atacicept, Atacicept: with loading doseUpdated Feb 2016
NCT00430495PHASE2COMPLETED

A Phase 2 Dose-finding Study of Atacicept in Subjects With Rheumatoid Arthritis (AUGUST I)

Sponsor · EMD SeronoCondition · Rheumatoid ArthritisIntervention · Atacicept, AtaciceptUpdated Feb 2016
NCT00624468PHASE2TERMINATED

Atacicept in Subjects With Optic Neuritis

Sponsor · EMD SeronoCondition · Optic NeuritisIntervention · Atacicept, Placebo matched to ataciceptUpdated Feb 2016
NCT01369628PHASE1TERMINATED

Atacicept in Lupus Nephritis Patients Taking Stable Regimen of Mycophenolate Mofetil

Sponsor · EMD SeronoCondition · Lupus NephritisIntervention · AtaciceptUpdated Oct 2013
NCT01440231PHASE2WITHDRAWN

Atacicept Demonstrating Dose RESponSe

Sponsor · EMD SeronoCondition · Systemic Lupus ErythematosusIntervention · Placebo, AtaciceptUpdated Aug 2013
Showing top 18 results. See all 18 results on CT.gov →